Ken Griffin Amgen Inc Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$262.75 - $319.31 $140 Million - $171 Million	-534,700 Reduced 30.47%	1,220,300 $381 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $177 Million - $213 Million	657,500 Added 59.91%	1,755,000 $499 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $4.99 Million - $5.62 Million	-19,500 Reduced 1.75%	1,097,500 $316 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $45.3 Million - $56.2 Million	207,000 Added 22.75%	1,117,000 $300 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $12.9 Million - $15.3 Million	60,200 Added 7.08%	910,000 $202 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $41.9 Million - $51 Million	-185,400 Reduced 17.91%	849,800 $205 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $26.3 Million - $33.4 Million	-114,900 Reduced 9.99%	1,035,200 $272 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $86.8 Million - $97.9 Million	-386,800 Reduced 25.17%	1,150,100 $259 Million

3,054

409M

7.19M

6.26M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.